Importance Cystic fibrosis, a genetic disorder defined by variants in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, affects more than 30 000 individuals in …

Since the first description of cystic fibrosis in 1938, there have been significant advances in
both quality of life and longevity for people living with this disease. In this article we describe …

Background Though weight gain has been reported in some clinical trials of CFTR
modulators, the effect of elexacaftor-tezacaftor-ivacaftor on body weight, body mass index …

Introduction Deterioration in mental health has been reported in a minority of individuals with
cystic fibrosis starting elexacafor/tezacaftor/ivacaftor (ELX/TEZ/IVA). We report our …

Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic
variants in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CFTR …

Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) is a new CFTR (Cystic Fibrosis
Transmembrane Conductance Regulator) modulator treatment, used over the last few years …

Recurrent and chronic bacterial infections are common in people with cystic fibrosis (CF)
and contribute to lung function decline. Antibiotics are the mainstay in the treatment of …

Mycobacterium abscessus is an opportunistic pathogen that mainly colonizes and infects
cystic fibrosis patients' lungs. M. abscessus is naturally resistant to many antibiotics such as …

Introduction Reports of neuropsychiatric symptoms proximal to cystic fibrosis
transmembrane conductance regulator (CFTR) modulator initiation are emerging, but their …

In cystic fibrosis (CF), pulmonary infection with Pseudomonas aeruginosa is a cause of
increased morbidity and mortality, especially in patients for whom infection becomes chronic …